ClinicalTrials.gg
CompletedNCT06318208Updated Mar 26, 2024

Pulmonary Function in Non-hospitalized Adults and Children After Mild COVID-19

An observational study in SARS-CoV-2 Infection, sponsored by University of Rostock. Completed at 1 site in Germany. Open to participants aged 6 Years to 60 Years. Per ClinicalTrials.gov, last updated 2024-03-26.

Sponsored by University of Rostock · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
110
Ages
6 Years to 60 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 226 studies in COVID-19 with a site in Germany — 21 open to participants now, 27 under way, 7 of them phase 3. COVID-19 · Germany.

Enrollment
71st of 94
110 · median 410
Started
2021
with 59 others
Observational
94 of 226
11 open now
Registered
220th of 226
by date

Among the 226 studies in COVID-19 with a site in Germany, this one is the 71st largest by enrollment of the 94 observational ones that give a count, is one of 60 that started in 2021, is one of 94 observational ones, and was the 220th registered.

COVID-19

7,996 studies on the registry are indexed under COVID-19; 469 are open to participants now.

Browse COVID-19 studies →

Open to participants now

21 of the 226 studies in COVID-19 with a site in Germany are open now. Recruiting first, the newest first:

16 more — sign in →

All 21 open studies →

A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →

Who these studies take

Of the 356 COVID-19 studies recruiting now, 205 (58%) set no upper age limit and 84 (24%) stop at 75 or younger; 90 take children under 18; 135 take healthy volunteers.

This study: 6 Years to 60 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 226 studies in COVID-19 with a site in Germany, or all of them as a file.
02

Study summary

The study investigates whether patients with mild SARS-CoV-2 infection, who stayed at home during their infection and weren't hospitalized, have any persisting sequelae in pulmonary function.

Therefore, 110 patients, aged 6-60 years, were recruited by telephone 4-12 weeks after laboratory-confirmed positive PCR and invited for a lung function testing. Every patient with abnormalities in pulmonary function was invited to a follow-up 3 months after the first appointment to assess changes in lung function values.

Patients with a pre-existing lung disease and smokers within the last five years were excluded beforehand.

Additionally to lung function testing we did a throat swab at each appointment to analyse via Multiplex PCR whether the patients had any other respiratory infection at the time of the pulmonary function testing.

Read the detailed description

110 patients, 90 adults and 20 children, were recruited. The lung function included LCI, FEV1, FVC and DLCO (Hb corrected). Additionally we did a throat swab at each appointment to analyse via Multiplex PCR whether the patients had any other respiratory infection at the time of the test.

03

Conditions studied

  • SARS-CoV-2 Infection

Browse trials for

Keywords

  • mild COVID-19
  • LCI
  • lung function
  • non-hospitalized COVID-19
04

Who can participate

Ages eligible
6 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

SARS-Covid -2 Infection 1 months before investigation

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • SARS-CoV-2 Infection, non-hospitalized during infection

Exclusion criteria

Exclusion Criteria:

  • Smoking, existing lung disease (, Asthma bronchiale)
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
110 participants (actual)
Patient registry
No

Interventions

  • Diagnostic testlung function testing

    lung function testing including LCI, FEV1, FVC, DLCO

06

What researchers measure

Primary outcomes

  1. Pulmonary function

    Pulmonary function after SARS-CoV-2 Infection

    Time frame: 4.3 - 11.3 weeks after positive PCR for SARS-CoV-2

Secondary outcomes

  1. Changes in pulmonary function

    Changes in pulmonary function towards the follow-up

    Time frame: 11.0 - 16.7 weeks after the first lung function testing

  2. Sociodemographic factors

    Relation of pulmonary function to sociodemographic factors

    Time frame: 9 months

07

Study locations

1 site
  • Kinder- und Jugendklinik Universitätsmedizin Rostock
    Rostock, 18057, Germany
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2021 to primary completion in Jan 2022, 8 months.

Of 1,640 non-industry observational studies under COVID-19, half reached primary completion within 14 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 30. This study's 8 months is below that.

Counting every sponsor, half of 1,774 studies reached it within 13 months; a quarter within 5 and three quarters within 29.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 17, 2024
First posted
Mar 19, 2024
StartActual
Apr 20, 2021
Primary completionActual
Jan 3, 2022
CompletionActual
Jan 3, 2022
Last update
Mar 26, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 26, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06318208
Lead sponsor
University of Rostock
Responsible party
Alexandra Rachel Görges (Principal Investigator, University of Rostock) — Principal investigator
First posted
Mar 19, 2024
Start date
Apr 20, 2021
Primary completion
Jan 3, 2022
Completion
Jan 3, 2022
Last update
Mar 26, 2024

Study contacts

Manfred Ballmann, Prof. Dr.
study director · UMR Kinder- und Jugendklinik

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion